News About: Pharm. Industry
The expected amount of annual claims of Erbitux is KRW 48 billion while the one of Revlimid is KRW 32 billion
It is known that the expected amounts of claims for the 4 anticancer drugs registered through the Risk Share Agreementare worth of KRW 90 billion.
Although they are anticancer drugs for a rare disease that has a smal...
Green Cross has targeted the Latin America with its blood fractionation product when its final goal is the U.S.Green Cross (CEO Eun-cheol Huh) announced on the 4th that the company won an order to supply Immunoglobulin IV Globulin S (IVIG-SN) worth of $ 5.72 million on the recent Brazili...
|
The pharmaceutical industry stated “Hard on generics while easy on OTC drugs”
The pharmaceutical industry suggested restricting thoughtless entries of generic products in the market. On the other hand, it requested easier approvals on OTC (Over The Counter) drugs.
At the 2015 Meeting of the Mi...
The distribution margin of GSK has been an issue again while the controversy is disadvantages of mid and small-sized companiesAs it is known that GSK will apply differential distribution margins on wholesale companies with the small monthly volume of businessby this April, the mid and small-sized whole...
|
.jpg)
How the tentative performance report shows the 10 listed pharmaceutical companies in 2014?
Although the pharmaceutical industry recorded a low growth rate in sales last year, it showed increasing performances in business profits and net profits.
According to the overall result of 10 listed pharmaceutical c...
The total foreigner-owned stock appraisement of listed pharmaceutical companies was KRW 2.33 trillion
It is known that the total foreigner-owned stock appraisement of listed pharmaceutical companies is worth of KRW 2.33 trillion.
According to the YakupDocCom’s analysis result of the present condition of stock apprais...
The countdown of the launch of the absolute winner in the obesity treatment market
The Ildong Pharmaceutical’s obesity treatment ‘Belviq (generic name: lorcaserin)‘, which recently acquired the sale approval from the Ministry of Food and Drug Safety, has attracted attention of the pharmaceutical mar...
‘Jakavi’ will start to get insurance benefits in this March…the medical industry and patients states “a tremendous welcome”
The myelofibrosis treatment ‘Jakavi (ruxolitinib)’ will finally be in the list of the insurance benefit.
According to the industry concerned on the 4th, Novartis Korea and the National Health Insurance Service recent...
Green Gross made KRW 975.3 billion sales, getting close to KRW 1 trillion…recording the top business profit in the industryThrough the fair disclosure on the 2nd, Green Cross (CEO Eun-cheol Huh) announced that it achieved 9.8% and 23.1% increased sales and business profits worth of KRW 975.3 and 97 ...
|
Kunwha Pharmaceutical replaced its CEO with a non-Korean… CEO Joo-hyung Lee resignedCEO of Kunwha Pharmaceutical is replaced with a foreigner.
Kunwha announced on the 2nd that CEO (Chief Executive Officer) Joo-hyun Lee resigned the position for his personal re...
|
